PHARMACY

PhRMA report lists almost 300 vaccines under development

BY Alaric DeArment

WASHINGTON — Drug makers in the United States are developing nearly 300 vaccines for preventing and treating diseases, according to a new report by a drug industry trade group.

The Pharmaceutical Research and Manufacturers of America released a report finding that the 295 vaccines — all of which are in clinical testing or  under review by the Food and Drug Administration — include 170 for infections diseases, 102 for cancers and eight for neurological disorders.

These include a therapeutic vaccine that increases the immune system’s response against HIV; a genetically modified treatment for cancer; and an immunotherapeutic vaccine for treating Alzheimer’s disease.

"Vaccines are one of the greatest achievements of biomedical science and public health," PhRMA president and CEO John Castellani said. "Over the past few decades, vaccinations have helped prevent and in some cases nearly eliminate contagious and deadly diseases affecting children and adults alike."


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

J.Tripp says:
Apr-26-2012 12:22 pm

DSN, thanks for highlighting the vaccines in development. I'm including a link to the report so your readers can see it in full. The report is available at http://bit.ly/Jd8hsy.

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Watson to buy Actavis for $5.6 billion

BY Alaric DeArment

PARSIPPANY, N.J. — Watson has announced its intention to acquire Actavis, the company said.

Following news reports Tuesday that the U.S.-based generic drug maker would acquire Switzerland-based Actavis, Watson announced Wednesday that it would buy the latter for $5.6 billion. News media had reported that the deal would be worth $5.9 billion, while there had been estimates in March that Watson would pay up to $7.3 billion.

"The acquisition of Actavis will create the third largest global generics company, substantially completing Watson’s expansion as a leading global generics company," Watson president and CEO Paul Bisaro said. "Actavis dramatically enhances our commercial position on a global basis and brings complementary products and capabilities in the United States."

Watson noted that Actavis operates in more than 40 countries and markets more than 1,000 products around the world, with more than 300 projects in its pipeline and 2011 sales of about $2.5 billion.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

FDA declines to approve Takeda diabetes drug

BY Alaric DeArment

DEERFIELD, Ill. — The Food and Drug Administration declined to approve a drug made by Takeda Pharmaceutical, the drug maker said.

Takeda announced that the FDA issued a complete response letter for its regulatory applications for the Type 2 diabetes drug alogliptin and a combination pill that includes alogliptin and pioglitazone, the active ingredient in the drug Actos.

A complete response letter means that the FDA has finished reviewing a drug approval application, but questions remain that preclude approval. In this case, the agency requested additional data about the drugs, which Takeda said it would supply from clinical trials.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

a.snn says:
Apr-27-2012 08:03 am

Takeda drug Actos has been linked to bladder cancer and this is still being investigated by the FDA

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?